[go: up one dir, main page]

GB9019841D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB9019841D0
GB9019841D0 GB909019841A GB9019841A GB9019841D0 GB 9019841 D0 GB9019841 D0 GB 9019841D0 GB 909019841 A GB909019841 A GB 909019841A GB 9019841 A GB9019841 A GB 9019841A GB 9019841 D0 GB9019841 D0 GB 9019841D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB909019841A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Priority to GB909019841A priority Critical patent/GB9019841D0/en
Publication of GB9019841D0 publication Critical patent/GB9019841D0/en
Priority to AU86247/91A priority patent/AU8624791A/en
Priority to PCT/GB1991/001545 priority patent/WO1992004334A1/en
Priority to JP3515781A priority patent/JPH06500791A/en
Priority to EP91916975A priority patent/EP0548227A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
GB909019841A 1990-09-11 1990-09-11 Compounds Pending GB9019841D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB909019841A GB9019841D0 (en) 1990-09-11 1990-09-11 Compounds
AU86247/91A AU8624791A (en) 1990-09-11 1991-09-10 Compounds
PCT/GB1991/001545 WO1992004334A1 (en) 1990-09-11 1991-09-10 Compounds
JP3515781A JPH06500791A (en) 1990-09-11 1991-09-10 Compound
EP91916975A EP0548227A1 (en) 1990-09-11 1991-09-10 Compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019841A GB9019841D0 (en) 1990-09-11 1990-09-11 Compounds

Publications (1)

Publication Number Publication Date
GB9019841D0 true GB9019841D0 (en) 1990-10-24

Family

ID=10682016

Family Applications (1)

Application Number Title Priority Date Filing Date
GB909019841A Pending GB9019841D0 (en) 1990-09-11 1990-09-11 Compounds

Country Status (5)

Country Link
EP (1) EP0548227A1 (en)
JP (1) JPH06500791A (en)
AU (1) AU8624791A (en)
GB (1) GB9019841D0 (en)
WO (1) WO1992004334A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
DE69939481D1 (en) 1998-09-17 2008-10-16 Bristol Myers Squibb Co METHOD FOR THE TREATMENT OF DIABETES USING AN AP2 INHIBITOR AND RELATED COMBINATIONS
AU2005201289B2 (en) * 1999-02-12 2008-04-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
AU781295B2 (en) * 1999-02-12 2005-05-12 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
US7390824B1 (en) 1999-09-07 2008-06-24 Bristol-Myers Squibb Company Method for treating diabetes employing an aP2 inhibitor and combination
AU2003224335A1 (en) * 2002-05-15 2003-12-02 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
AU2013370422A1 (en) 2012-12-28 2015-07-02 The Board Of Trustees Of The University Of Arkansas Indole compounds for use in treating inflammation and cancer
CA2907853A1 (en) 2013-04-19 2014-10-23 The Board Of Trustees Of The University Of Arkansas Combretastatin analogs
AU2015240880A1 (en) * 2014-03-31 2016-09-15 Bioventures, Llc Disubstituted triazole analogs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1206403A (en) * 1966-12-15 1970-09-23 Wyeth John & Brother Ltd Oxazoles
FR2082166A5 (en) * 1970-03-05 1971-12-10 Aries Robert Salicyclic acid - substd oxazolyl alkanoates - analgesics, antipyretic antiinflammatories, antirheumatics
FR2104651A1 (en) * 1970-04-27 1972-04-21 Aries Robert Pyridylmethoxycarbonylalkyl thiazoles and oxazoles - - analgesics, tranquillisers, antipyretics, antiinflammatories, and a
US3948932A (en) * 1973-05-29 1976-04-06 Miles Laboratories, Inc. Phenyl- and (substituted)-phenyl-1,2,3-triazole-alkanoic and -alkenoic acids

Also Published As

Publication number Publication date
AU8624791A (en) 1992-03-30
WO1992004334A1 (en) 1992-03-19
JPH06500791A (en) 1994-01-27
EP0548227A1 (en) 1993-06-30

Similar Documents

Publication Publication Date Title
GB9012592D0 (en) Compounds
AP9100313A0 (en) Compounds
GB9001245D0 (en) Compounds
AP9100314A0 (en) Compounds
GB9011332D0 (en) Compounds
GB9009469D0 (en) Compounds
GB9019841D0 (en) Compounds
GB9013016D0 (en) Compounds
GB9007965D0 (en) Compounds
GB9007967D0 (en) Compounds
GB9002834D0 (en) Compounds
GB9007738D0 (en) Compounds
GB9011693D0 (en) Compounds
GB9013994D0 (en) Compounds
GB9010266D0 (en) Compounds
GB9009478D0 (en) Compounds
GB9006112D0 (en) Compounds
GB9008872D0 (en) Compounds
GB9008556D0 (en) Compounds
GB9008507D0 (en) Compounds
GB9008330D0 (en) Compounds
GB9007984D0 (en) Compounds
GB9011850D0 (en) Compounds
GB9012795D0 (en) Compounds
GB9013379D0 (en) Compounds